智通财经APP讯，一脉阳光(02522)发布公告，公司近日与甘肃省庆阳市人民政府以及公司孵化的医学影 像人工智能公司上海影禾医脉智能科技有限公司(影禾医脉)订立战略框架合作协议。根据该战略框架合 作协议，三方拟就建设共享医学影像中心、影响云索引互联互通互认平台和医疗健康可信数据空间开展 战略合作。战略合作将通过建设区域共享型影像诊断中心与数字化平台，有效整合医疗资源，为当地医 疗机构提供标准化、高质量的医学影像服务。战略合作还将推进医疗信息化平台建设，构建互联互通互 认体系与健康可信数据空间，助力落实分级诊疗、加强各级医疗机构协同、解决数据孤岛与重复检查等 问题，提升资源利用效率，并推动医疗数据资产化进程。 董事会认为，战略合作将助力集团提升区域医疗资源整合与治理能力，进一步拓展西北地区市场，扩大 医学影像共享中心版图，符合公司及其股东的整体利益。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Jiangxi Rimag Group Co., Ltd. 江西一脈陽光集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2522) 自願公告 與慶陽市政府及影禾醫脈訂立戰略框架合作協議 本公告由江西一脈陽光集團股份有限公司（「本公司」，連同其附屬公司統稱「本集 團」）董事（「董事」）會（「董事會」）自願作出，以知會本公司股東及潛在投資者本 集團最新的業務發展狀況。 董事會欣然宣佈，本公司近日與甘肅省慶陽市人民政府（「慶陽市政府」）以及本公 司孵化的醫學影像人工智能公司上海影禾醫脈智能科技有限公司（「影禾醫脈」）訂 立戰略框架合作協議。根據該戰略框架合作協議，三方擬就建設共享醫學影像中 心、影響雲索引互聯互通互認平台和醫療健康可信數據空間開展戰略合作（「戰略 合作」）。戰略合作將通過建設區域共享型影像診斷中心與數字化平台，有效整合 醫療資源，為當地醫療機構提供標準化、高質量的醫學 ...

Group 1 - The China International Import Expo (CIIE) has expanded significantly since its inception in 2018, with total exhibition area increasing from 270,000 square meters to 430,000 square meters, a growth of over 55% [1] - CIIE has attracted a cumulative total of 23,000 foreign exhibitors and has generated an intended transaction value exceeding $500 billion, showcasing approximately 3,000 new products, technologies, and services across various sectors including healthcare, automotive, and green technology [1] - The event has seen participation from 31 countries as guest countries and over 180 countries and regions, including 151 countries involved in the Belt and Road Initiative, with more than 1,200 supporting activities held [1] Group 2 - Shanghai has emerged as a global innovation hub in the biopharmaceutical industry, with 8 Class I innovative drugs and 7 Class III innovative medical devices approved for market this year, alongside 4 Shanghai-produced drugs entering major international markets [3] - The city has established 11 major scientific infrastructure projects, with 4 under construction and 5 planned, amounting to a total investment of approximately 35 billion yuan [5] - Shanghai scientists published 138 papers in top international journals such as Cell, Nature, and Science from January to September this year, accounting for 30.1% of the national total, while R&D expenditure as a percentage of GDP increased from 3.4% to around 4.4% over the past decade [5]

Core Viewpoint - The article highlights the innovative journey of Wang Shengxue, founder of Suzhou Yingchuang Medical Technology Co., Ltd., who aims to revolutionize medical imaging safety through the development of self-blood contrast agents, addressing long-standing safety concerns in traditional contrast agents [5][6][12]. Group 1: Entrepreneurial Journey - Wang Shengxue transitioned from investment banking to entrepreneurship, driven by a desire to solve clinical pain points in the field of medical imaging [8][10]. - The company was founded in September 2024, focusing on cutting-edge technology in the medical sector [10]. Group 2: Technological Innovation - The self-blood NOCA technology represents a significant advancement in medical imaging, utilizing the patient's own blood to enhance MRI scans, thus eliminating the risks associated with traditional metal-based contrast agents [12]. - This innovative approach has completed large animal experiments and is moving towards human trials, positioning the company at the forefront of global medical technology [12]. Group 3: Management Philosophy - As a non-technical CEO, Wang Shengxue emphasizes a management philosophy based on trust in the project and the team's expertise, ensuring that professionals handle their respective areas [14]. - Participation in the "Pudong Science and Technology - Haiwang Summit CEO Training Camp" has further refined her management approach, allowing her to understand the operational models of other high-tech industries [16][18]. Group 4: Industry Insights - The training camp provided insights into various hard technology sectors, enabling Wang to learn from the successes and challenges faced by entrepreneurs in different fields, which can be applied to the medical industry [18]. - The curriculum of the training camp was designed to offer practical knowledge and real-world case studies, helping early-stage entrepreneurs avoid common pitfalls [18].

Core Viewpoint - The company, Yimai Sunshine (02522), has seen its stock price increase by over 4%, currently trading at 15.46 HKD, with a transaction volume of 51.26 million HKD, following the announcement of a significant investment in Shanghai Yinghe Medical Technology Co., Ltd. [1] Group 1: Investment and Strategic Moves - Yimai Sunshine has entered into a capital increase subscription agreement with Shanghai Yinghe Medical Technology Co., Ltd., investing nearly 100 million RMB to subscribe to the new registered capital of Yinghe Medical [1] - This investment will enhance the company's total equity stake in Yinghe Medical, aligning with its strategy in the medical imaging AI sector, which integrates medical imaging data, AI foundational models, and imaging center scenarios [1] Group 2: Achievements and Future Prospects - By the end of October 2025, a medical imaging database co-built by the three parties successfully achieved its first commercial conversion contract in a data sandbox environment, providing a large model training service valued at tens of millions of RMB [1] - This achievement signifies a substantial breakthrough for the company in the marketization and value realization of medical imaging data assets, further deepening its strategic layout in the data business sector and enhancing its comprehensive competitiveness in the medical imaging AI field [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Jiangxi Rimag Group Co., Ltd. 江西一脈陽光集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2522） 自願公告 醫學影像數據共建合作項目 本公告由江西一脈陽光集團股份有限公司（「本公司」，連同其附屬公司統稱為「本 集團」）董事（「董事」）會（「董事會」）自願作出。 董事會欣然宣佈，於2025年10月，本集團之附屬公司北京一脈陽光醫學信息技術 有限公司（「北京一脈」）與北京數據先行區服務有限公司（「北京先行區」）及北京 國際算力服務有限公司（「北京算力」）共同簽署《數據共建合作協議》。北京先行區 為經北京市經濟和信息化局授權開展北京人工智能數據沙盒（「數據沙盒」）試點工 作的運營主體，負責提供數據處理、合規評審及模型訓練支持；北京算力則提供 可信存儲與算力資源等技術基礎設施。 江西一脈陽光集團股份有限公司 本次合作旨在依托數據沙盒的合規監管框架，基於 ...

Core Viewpoint - The company has entered into an investment agreement to acquire additional equity in Yinghe Medical Technology, recognizing the rapid growth potential in the medical imaging AI sector and the increasing demand for precise and efficient imaging diagnostics [1][2][3] Group 1: Investment Details - The company will invest nearly 100 million RMB to subscribe to the new registered capital of Yinghe Medical Technology, which will increase its total equity stake in the company [1] - This investment is part of the company's strategy to enhance its presence in the medical imaging AI sector, aligning with its long-term development plans [2] Group 2: Strategic Importance - The investment is expected to activate a "twin incubation" development mechanism, leveraging the company's quality data resources and Yinghe's AI technology to create a mutually beneficial growth environment [2] - By enhancing its industrial chain layout through this investment, the company aims to transition towards a data-driven service model, improving its core competitive strength in the industry [2] Group 3: Market Positioning - The investment will significantly improve the diagnostic accuracy and efficiency of the company's imaging centers and partner medical institutions, better meeting clinical needs [2] - This strategic move is anticipated to strengthen the company's position in the rapidly growing imaging AI field, allowing it to seize industry development opportunities and achieve sustained business growth [3]

Core Viewpoint - The company has signed a capital increase agreement with Shanghai Yinghe Medical Technology Co., Ltd., investing nearly 100 million RMB to enhance its stake, reflecting a strategic move to strengthen its position in the rapidly growing medical imaging AI sector [1][2]. Group 1: Investment and Strategic Importance - The investment is part of the company's strategy to implement a three-in-one model of medical imaging AI, which includes medical imaging data, AI foundational models, and imaging center scenarios [2]. - This capital connection is expected to activate a "twin incubation" development mechanism, leveraging the company's accumulated quality data resources and Yinghe Medical's AI technology to create a mutually beneficial development cycle [2][3]. Group 2: Market Position and Competitive Advantage - The investment will enhance the company's industrial chain layout, improve service quality, and strengthen its competitive position in the fast-growing imaging AI field [2][3]. - By utilizing Yinghe Medical's technological advantages, the company aims to transition towards a data-driven service model, thereby increasing its core competitiveness in the industry [2]. - The anticipated outcome of this investment is to solidify the company's leadership position in China's medical imaging AI sector through the construction of a comprehensive "data + algorithm + scenario" closed-loop system [3].

Core Viewpoint - The company has entered into a capital increase agreement with Shanghai Yinghe Medical Technology Co., Ltd., investing nearly 100 million RMB to enhance its stake, reflecting a strategic move to strengthen its position in the rapidly growing medical imaging AI sector [1][2]. Group 1 - The investment aligns with the company's strategy of integrating medical imaging data, AI models, and imaging center scenarios, enhancing its long-term development in the medical imaging field [2]. - The partnership with Yinghe Medical will activate a "twin incubation" mechanism, leveraging the company's quality data resources and Yinghe's AI technology to create a beneficial interaction between information, data, and AI capabilities [2]. - The investment is expected to improve the company's competitive position in the fast-growing imaging AI market, enabling sustained business growth [2][3]. Group 2 - The investment will enhance the company's layout in the medical imaging industry chain, improving the precision and efficiency of imaging diagnostic services [3]. - By utilizing Yinghe's technological advantages, the company aims to transition towards a data-driven service model, thereby increasing its core competitiveness in the industry [2][3]. - The establishment of a "data + algorithm + scenario" closed-loop system will solidify the company's leadership position in China's medical imaging AI sector [3].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Jiangxi Rimag Group Co., Ltd. 江西一脈陽光集團股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2522） 自願公告 增資於一家醫學影像人工智能公司 本公告由江西一脈陽光集團股份有限公司（「本公司」或「一脈陽光」），連同其附屬 公司統稱（「本集團」）董事（「董事」）會（「董事會」）自願作出。 董事會欣然宣佈，於2025年10月29日（「簽署日」），本公司與上海影禾醫脈智能科 技有限公司（「影禾醫脈」）及其相關各方訂立《增資認購協議》（「協議」）。據此， 本公司以總代價近億元人民幣認購影禾醫脈的新增註冊資本。本次交易完成後， 本公司於影禾醫脈的持股總權益將進一步提升。 董事會認為，醫學影像人工智能作為醫療科技領域未來的核心發展方向，正迎來 市場需求快速釋放的黃金階段。隨著醫療數字化轉型加速，臨床對精準化、高效 化影像診斷的需求日益迫切，這一領域的市場空間將 ...